ZE46-0134

· Lomond Therapeutics Holdings, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for ZE46-0134, covering 2025-12-09 to 2025-12-31. Get the full timeline:

Most recent: Clinical Trial Update: Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

See pricing